Imatinib
Adjuvant Study 1 (ACOSOG Z9001)
Novartis · Phase 3 · Completed · Enrollment 732
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg for 12 months | n/r |
A count stays a count. This page does not turn a count into a percent.
GIST
Programs, trials, and reported response and survival for gastrointestinal stromal tumor.
Imatinib
Novartis · Phase 3 · Completed · Enrollment 732
| Arm | Reported safety |
|---|---|
| Imatinib 400 mg for 12 months | n/r |
A count stays a count. This page does not turn a count into a percent.